What ICD (International Classification of Diseases) codes should be used for a patient with hepatocellular disease undergoing testing for hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ICD Codes for Hepatitis Testing in Patients with Hepatocellular Disease

For patients with hepatocellular disease undergoing testing for hepatitis, the primary diagnosis code should be the specific hepatocellular disease code (such as K76.0 for fatty liver or K74.6 for cirrhosis), followed by the appropriate Z code for hepatitis screening (Z11.59). 1

Primary Diagnostic Codes for Hepatocellular Disease

  • K76.0 - Fatty liver, not elsewhere classified
  • K74.6 - Other and unspecified cirrhosis of liver
  • K76.9 - Liver disease, unspecified
  • C22.0 - Liver cell carcinoma (if hepatocellular carcinoma is confirmed)
  • K70.30 - Alcoholic cirrhosis of liver without ascites
  • K70.31 - Alcoholic cirrhosis of liver with ascites

Secondary Z Codes for Hepatitis Testing

  • Z11.59 - Encounter for screening for other viral diseases
  • Z20.5 - Contact with and (suspected) exposure to viral hepatitis
  • Z22.51 - Carrier of viral hepatitis B
  • Z22.52 - Carrier of viral hepatitis C

Coding Algorithm Based on Clinical Context

For Initial Hepatitis Screening:

  1. Code the hepatocellular disease first (K76.x, K74.x, C22.0)
  2. Add Z11.59 (screening for viral diseases)

For Testing Due to Known Exposure:

  1. Code the hepatocellular disease first
  2. Add Z20.5 (exposure to viral hepatitis)

For Follow-up Testing in Known Carriers:

  1. Code the hepatocellular disease first
  2. Add Z22.51 (carrier of HBV) or Z22.52 (carrier of HCV)

Clinical Rationale for Hepatitis Testing in Hepatocellular Disease

Hepatitis B (HBV) and hepatitis C (HCV) are the most important causes of chronic liver disease and hepatocellular carcinoma (HCC) worldwide 1. The association between chronic viral hepatitis and hepatocellular disease is well-established:

  • HBV and HCV increase the risk of HCC nearly 7-fold and 4-fold respectively 2
  • Early identification of viral hepatitis allows for antiviral treatment that can reduce liver-related morbidity and mortality 1
  • Screening for hepatitis is recommended for all patients with cirrhosis and those at high risk for HCC 1

Documentation Requirements for Proper Coding

To support proper ICD coding, ensure documentation includes:

  1. The specific hepatocellular disease diagnosis
  2. Clinical rationale for hepatitis testing
  3. Type of hepatitis being tested for (HBV, HCV, or both)
  4. Risk factors for viral hepatitis
  5. Previous history of hepatitis testing or treatment

Common Pitfalls to Avoid

  • Don't use screening codes alone without the underlying hepatocellular disease code
  • Don't code suspected hepatitis as confirmed until test results are available
  • Don't use general screening codes (Z00.00) when specific hepatitis screening codes exist
  • Don't omit Z codes that provide context for the testing being performed
  • Don't use acute hepatitis codes (B15-B19) for screening purposes

Special Considerations

For patients undergoing imaging studies as part of their evaluation, ensure that the appropriate indication for the imaging is documented. According to LI-RADS guidelines, hepatitis testing results are essential for proper risk stratification and interpretation of imaging findings 3.

When hepatitis testing is performed as part of a comprehensive HCC surveillance program, the coding should reflect both the underlying liver disease and the screening purpose to ensure proper reimbursement and clinical tracking 1, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Liver Imaging Reporting and Data System (LI-RADS) for Hepatocellular Carcinoma (HCC) Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk.

Mayo Clinic proceedings. Innovations, quality & outcomes, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.